Literature DB >> 28653114

Precision medicine approach to genetic cardiomyopathy.

K Filonenko1, H A Katus1,2, B Meder3,4.   

Abstract

Precision medicine aims to achieve improved survival by strategies that recognize the genetic and phenotypic individuality of patients and stratify treatment accordingly. Genetic cardiomyopathies represent an ideal disease group to fully embark on this concept: they are in total frequent diseases with a marked morbidity and mortality and there is ample knowledge about their predisposing genetic factors and associated functional mechanisms. The current review highlights the genetic etiology and gives examples of the diverse treatment strategies that are envisaged in the future.

Entities:  

Keywords:  Arrhythmia; Clustered regularly interspaced short palindromic repeats; Gene repair; Genetic testing; Genome-wide association study; Mutations; Risk assessment; Sudden cardiac death

Mesh：

Year:  2017        PMID： 28653114     DOI： 10.1007/s00059-017-4592-z

Source DB:  PubMed          Journal:  Herz        ISSN： 0340-9937            Impact factor:   1.443


  88 in total

1.  Familial restrictive cardiomyopathy with atrioventricular block and skeletal myopathy.

Authors:  A P Fitzpatrick; L M Shapiro; A F Rickards; P A Poole-Wilson
Journal:  Br Heart J       Date:  1990-02

2.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.

Authors:  Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

3.  Furthering the link between the sarcomere and primary cardiomyopathies: restrictive cardiomyopathy associated with multiple mutations in genes previously associated with hypertrophic or dilated cardiomyopathy.

Authors:  Colleen Caleshu; Rahul Sakhuja; Robert L Nussbaum; Nelson B Schiller; Philip C Ursell; Celeste Eng; Teresa De Marco; Dana McGlothlin; Esteban González Burchard; J Eduardo Rame
Journal:  Am J Med Genet A       Date:  2011-08-05       Impact factor: 2.802

4.  A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy.

Authors:  Benjamin Meder; Frank Rühle; Tanja Weis; Georg Homuth; Andreas Keller; Jennifer Franke; Barbara Peil; Justo Lorenzo Bermejo; Karen Frese; Andreas Huge; Anika Witten; Britta Vogel; Jan Haas; Uwe Völker; Florian Ernst; Alexander Teumer; Philipp Ehlermann; Christian Zugck; Frauke Friedrichs; Heyo Kroemer; Marcus Dörr; Wolfgang Hoffmann; Bernhard Maisch; Sabine Pankuweit; Volker Ruppert; Thomas Scheffold; Uwe Kühl; Hans-Peter Schultheiss; Reinhold Kreutz; Georg Ertl; Christiane Angermann; Philippe Charron; Eric Villard; Françoise Gary; Richard Isnard; Michel Komajda; Matthias Lutz; Thomas Meitinger; Moritz F Sinner; H-Erich Wichmann; Michael Krawczak; Boris Ivandic; Dieter Weichenhan; Goetz Gelbrich; Nour-Eddine El-Mokhtari; Stefan Schreiber; Stephan B Felix; Gerd Hasenfuß; Arne Pfeufer; Norbert Hübner; Stefan Kääb; Eloisa Arbustini; Wolfgang Rottbauer; Norbert Frey; Monika Stoll; Hugo A Katus
Journal:  Eur Heart J       Date:  2013-07-12       Impact factor: 29.983

5.  Malignant hypertrophic cardiomyopathy caused by the Arg723Gly mutation in beta-myosin heavy chain gene.

Authors:  M Enjuto; A Francino; F Navarro-López; D Viles; J C Paré; A M Ballesta
Journal:  J Mol Cell Cardiol       Date:  2000-12       Impact factor: 5.000

6.  Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations.

Authors:  Barbara Bauce; Cristina Basso; Alessandra Rampazzo; Giorgia Beffagna; Luciano Daliento; Gianfranco Frigo; Sandro Malacrida; Luca Settimo; GianAntonio Danieli; Gaetano Thiene; Andrea Nava
Journal:  Eur Heart J       Date:  2005-06-07       Impact factor: 29.983

7.  Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death.

Authors:  A J Marian; Q T Yu; R Workman; G Greve; R Roberts
Journal:  Lancet       Date:  1993-10-30       Impact factor: 79.321

8.  Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy.

Authors:  R Anan; G Greve; L Thierfelder; H Watkins; W J McKenna; S Solomon; C Vecchio; H Shono; S Nakao; H Tanaka
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

9.  Familial dilated cardiomyopathy and isolated left ventricular noncompaction associated with lamin A/C gene mutations.

Authors:  Manuel Hermida-Prieto; Lorenzo Monserrat; Alfonso Castro-Beiras; Rafael Laredo; Rafaela Soler; Jesus Peteiro; Esther Rodríguez; Beatriz Bouzas; Nemesio Alvarez; Javier Muñiz; Marisa Crespo-Leiro
Journal:  Am J Cardiol       Date:  2004-07-01       Impact factor: 2.778

Review 10.  Update on hypertrophic cardiomyopathy and a guide to the guidelines.

Authors:  Srijita Sen-Chowdhry; Daniel Jacoby; James C Moon; William J McKenna
Journal:  Nat Rev Cardiol       Date:  2016-09-29       Impact factor: 32.419
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.